Solvay Pharmaceuticals awarded $298 million, five-year contract by U.S. department of Health & Human Services
Contract Covers Development of Cell-Based Influenza Vaccines and Planning for a U.S. Manufacturing Facility
Solvay Pharmaceuticals announced that it was awarded a $298 million, five-year contract from the United States Department of Health and Human services (HHS) to develop cell-based influenza vaccines and plan for domestic manufacturing capacity in the U.S.
The milestone-based contract, awarded to Solvay Pharmaceuticals in the U.S., covers the development and testing of new influenza vaccines including pandemic vaccines that are produced using cell-based technology and the development of a master plan to manufacture, formulate, fill and package annual and pandemic influenza vaccines in a new U.S.-based facility. Other activities that will be supported by the award include the submission of an Investigational New Drug (IND) application, pre-clinical and clinical studies for seasonal and pandemic-like vaccines, adjuvant development and a Biologics License Application (BLA) allowing for the distribution and marketing of influenza vaccines in the U.S. The award also includes funding to support development and design costs associated with establishing a new U.S.-based influenza vaccine manufacturing facility.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
